CO6501183A2 - Piperidinas sustituidas como antagonistas de ccr3 - Google Patents

Piperidinas sustituidas como antagonistas de ccr3

Info

Publication number
CO6501183A2
CO6501183A2 CO11127672A CO11127672A CO6501183A2 CO 6501183 A2 CO6501183 A2 CO 6501183A2 CO 11127672 A CO11127672 A CO 11127672A CO 11127672 A CO11127672 A CO 11127672A CO 6501183 A2 CO6501183 A2 CO 6501183A2
Authority
CO
Colombia
Prior art keywords
antigonist
piperidins
ccr3
replaced
present
Prior art date
Application number
CO11127672A
Other languages
English (en)
Inventor
Marc Grundl
Horst Dollinger
Riccardo Giovannini
Christoph Hoenke
Matthias Hoffmann
Jan Kriegl
Domnic Martyres
George Rast
Peter Seither
Original Assignee
Boheringer Ingelheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boheringer Ingelheim Internat Gmbh filed Critical Boheringer Ingelheim Internat Gmbh
Publication of CO6501183A2 publication Critical patent/CO6501183A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Objeto de la presente invención son compuestos novedosos sustituidos de la fórmula 1, en la que A, R 1 , R 2 , R 3 y se definen como en la descripción. Otro objeto de la presente invención es proporcionar antagonistas de CCR 3 , más particularmente proporcionar composiciones farmacéuticas que comprenden un vehículo farmacéuticamente aceptable y una cantidad terapéuticamente eficaz de al menos uno de los compuestos de la presente invención o una sal farmacéuticamente aceptable del mismo.
CO11127672A 2009-04-08 2011-09-29 Piperidinas sustituidas como antagonistas de ccr3 CO6501183A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157653 2009-04-08
EP09174917 2009-11-03

Publications (1)

Publication Number Publication Date
CO6501183A2 true CO6501183A2 (es) 2012-08-15

Family

ID=42561233

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11127672A CO6501183A2 (es) 2009-04-08 2011-09-29 Piperidinas sustituidas como antagonistas de ccr3

Country Status (31)

Country Link
US (3) US8278302B2 (es)
EP (1) EP2417120B1 (es)
JP (1) JP5466246B2 (es)
KR (1) KR101690979B1 (es)
CN (1) CN102388032B (es)
AP (1) AP2989A (es)
AR (1) AR076228A1 (es)
AU (1) AU2010233849B2 (es)
BR (2) BRPI1013821B1 (es)
CA (1) CA2753151C (es)
CL (1) CL2011002197A1 (es)
CO (1) CO6501183A2 (es)
DK (1) DK2417120T3 (es)
EA (1) EA021072B1 (es)
EC (1) ECSP11011427A (es)
ES (1) ES2613696T3 (es)
GE (1) GEP20135863B (es)
HK (1) HK1164295A1 (es)
HU (1) HUE030787T2 (es)
IL (1) IL214309A (es)
MA (1) MA33178B1 (es)
MX (1) MX2011010584A (es)
MY (1) MY161903A (es)
NZ (1) NZ594597A (es)
PE (1) PE20120135A1 (es)
PL (1) PL2417120T3 (es)
PT (1) PT2417120T (es)
SG (2) SG10201401347QA (es)
TW (1) TWI466880B (es)
UY (1) UY32547A (es)
WO (1) WO2010115836A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013079696A1 (en) * 2011-12-01 2013-06-06 Glaxo Group Limited Methods of treatment and prevention of eye diseases
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
TW201410677A (zh) 2012-07-31 2014-03-16 Kyowa Hakko Kirin Co Ltd 縮環雜環化合物
WO2015012332A1 (ja) * 2013-07-24 2015-01-29 田辺三菱製薬株式会社 眼科疾患治療剤
KR102633122B1 (ko) * 2014-08-01 2024-02-05 누에볼루션 에이/에스 브로모도메인에 대하여 활성을 갖는 화합물
EP3613435A1 (en) 2015-01-28 2020-02-26 Universite De Bordeaux Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease
CN109152866B (zh) * 2016-03-31 2021-10-15 国立研究开发法人国立长寿医疗研究中心 牙科用前处理材料及牙组织再生试剂盒
IL269743B (en) * 2017-04-05 2022-09-01 Alkahest Inc Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
KR20190131078A (ko) * 2017-04-05 2019-11-25 알카헤스트 인코포레이티드 Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물
MX2019013275A (es) 2017-05-12 2020-07-27 Enanta Pharm Inc Inhibidores de la quinasa 1 reguladora de la señal de apoptosis y métodos de uso de estos.
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN107602457A (zh) * 2017-10-10 2018-01-19 重庆奥舍生物化工有限公司 一锅法合成6‑甲基‑2‑氨基‑异烟酸的方法
WO2019075351A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATING PRURIT, XEROSIS AND ASSOCIATED DISEASE USING CCR3 INHIBITORS
WO2019213239A1 (en) 2018-05-02 2019-11-07 Enanta Pharmaceuticals Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
IL278368B1 (en) 2018-05-02 2024-02-01 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods for its use
MX2020011114A (es) 2018-05-15 2021-01-29 Alkahest Inc Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa.
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
SG11202102105VA (en) * 2018-09-26 2021-04-29 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
WO2023076679A1 (en) 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) * 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) * 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
AU2335699A (en) 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
JP2002501898A (ja) * 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性の環状アミン調節剤
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
DE10233366A1 (de) 2002-07-23 2004-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
CA2543419A1 (en) * 2003-10-24 2005-05-06 Leyi Gong Ccr3 receptor antagonists
ATE428422T1 (de) * 2004-02-05 2009-05-15 Schering Corp Piperidin-derivate als ccr3-antagonisten
WO2005095339A1 (en) 2004-03-31 2005-10-13 Pfizer Products Inc. Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors
JP2007537180A (ja) 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規置換チオフェンカルボキサミド、それらの調製方法及び薬物としてのそれらの使用
MX2007004051A (es) 2004-10-07 2007-05-24 Boehringer Ingelheim Int Pi3-quinasas.
JP2006137718A (ja) * 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
WO2006114371A1 (de) 2005-04-28 2006-11-02 Boehringer Ingelheim International Gmbh Neue verbindungen zur behandlung von entzündlichen erkrankungen
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
CA2647448A1 (en) 2006-04-12 2007-10-18 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
US20130023517A1 (en) 2013-01-24
MA33178B1 (fr) 2012-04-02
JP5466246B2 (ja) 2014-04-09
AP2989A (en) 2014-09-30
BRPI1013821B1 (pt) 2020-03-31
EA201101398A1 (ru) 2012-04-30
HUE030787T2 (en) 2017-06-28
GEP20135863B (en) 2013-06-25
UY32547A (es) 2010-11-30
ES2613696T3 (es) 2017-05-25
AP2011005817A0 (en) 2011-08-31
BR122019017002B1 (pt) 2021-08-10
PT2417120T (pt) 2017-02-03
AU2010233849B2 (en) 2014-05-08
BRPI1013821A8 (pt) 2019-09-17
PL2417120T3 (pl) 2017-04-28
DK2417120T3 (en) 2016-12-19
CN102388032B (zh) 2015-01-14
NZ594597A (en) 2014-02-28
EP2417120A1 (en) 2012-02-15
EA021072B1 (ru) 2015-03-31
US8278302B2 (en) 2012-10-02
PE20120135A1 (es) 2012-02-29
BRPI1013821A2 (pt) 2016-04-05
JP2012514024A (ja) 2012-06-21
KR101690979B1 (ko) 2016-12-29
TW201103901A (en) 2011-02-01
CA2753151A1 (en) 2010-10-14
AU2010233849A1 (en) 2011-08-18
HK1164295A1 (en) 2012-09-21
IL214309A (en) 2014-02-27
IL214309A0 (en) 2011-09-27
US20100261687A1 (en) 2010-10-14
WO2010115836A4 (en) 2010-12-09
AR076228A1 (es) 2011-05-26
USRE45323E1 (en) 2015-01-06
US8653075B2 (en) 2014-02-18
EP2417120B1 (en) 2016-10-26
SG175079A1 (en) 2011-11-28
ECSP11011427A (es) 2011-11-30
KR20120034590A (ko) 2012-04-12
MX2011010584A (es) 2011-10-19
TWI466880B (zh) 2015-01-01
CL2011002197A1 (es) 2012-03-23
MY161903A (en) 2017-05-15
SG10201401347QA (en) 2014-05-29
CN102388032A (zh) 2012-03-21
WO2010115836A1 (en) 2010-10-14
CA2753151C (en) 2017-02-28

Similar Documents

Publication Publication Date Title
CO6501183A2 (es) Piperidinas sustituidas como antagonistas de ccr3
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
SV2011003853A (es) Compuestos organicos
UY32730A (es) Inhibidores de cyp17
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
DOP2009000278A (es) Derivados de bencimidazol
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
ECSP11011415A (es) Piperidinas sustituidas como antagonistas de ccr3.
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
CR20110093A (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
CL2012000263A1 (es) Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
ECSP11011473A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída
PE20170427A1 (es) Peptidos como agonistas de la oxitocina
CO6361921A2 (es) 3-aminociclopentancarboxamidas
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
DOP2012000078A (es) Derivados de espirolactama y usos de los mismos
UY32852A (es) [4-(5-aminometil-fenil)-piperidin-1-il]-1h-indol-3-il]-metanonas disustituidas.
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio

Legal Events

Date Code Title Description
FG Application granted